Page 3 - Les Meilleurs doctors pour votre Chimiothérapie contre la leucémie - TOP 97 des médecins

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Le Dr Eckhart Weidmann dirige le secteur d'Hématologie à la Clinique Nordwest. Il est spécialisé dans le traitement des troubles sanguins et possède plus de 30 ans d'expérience.

• L'un des meilleurs médecins spécialistes du lymphome non hodgkinien
• Professeur possédant une vaste expertise académique et clinique
• Se concentre sur la leucémie et les autres troubles sanguins

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Spécialiste israélien de premier plan en immunothérapie du cancer du poumon – le Prof. Peled dirige l'Unité de cancérologie thoracique au Davidoff Cancer Center.

• Expert en médecine personnalisée et en immuno-oncologie
• Récipiendaire du prix MERIT de l'ASCO pour la recherche sur le cancer du poumon
• Président du Comité de détection précoce et de prévention de l'IASLC
• Formation de perfectionnement (Fellowship) à l'Université du Colorado à Denver

Le Professeur Bosch est un leader mondialement reconnu dans le domaine de la Leucémie Lymphoïde Chronique (LLC), pionnier de nouveaux traitements et technologies pour les maladies hématologiques.

• Plus de 30 ans d'expérience en hématologie, spécialisé dans les lymphomes et la LLC
• Dirige des essais cliniques de phase 1 à phase 3, offrant de nouvelles thérapies aux patients
• Chef du Service d'Hématologie à l'Institut d'Oncologie IOB et à l'Hôpital Universitaire Vall d'Hebron
• A publié plus de 100 articles dans des revues de premier plan telles que The New England Journal of Medicine

La Professeure Myriam Ben Arush, spécialiste internationalement reconnue en Oncologie Pédiatrique, dirige la Division Pédiatrique à l'Hôpital pour enfants Ruth Rappaport.

• Récipiendaire du Prix du Ministère de la Santé pour son travail exceptionnel
• Décernée Chevalier de la Légion d'Honneur en France
• Reconnue par l'Association Médicale Mondiale comme l'un des médecins les plus attentifs au monde
• Membre du groupe d'oncologie pédiatrique aux États-Unis et de plusieurs sociétés européennes de cancérologie

Spécialiste en radiothérapie axé sur la chimiothérapie de la leucémie – le Dr Drumea apporte une expertise ciblée au Centre médical Rambam.

• Oncologue se concentrant sur le traitement précis du cancer
• Utilise des techniques de radiothérapie avancées
• Travaille au Centre médical Rambam – un hôpital israélien de premier plan

Directrice de l'Institut d'oncologie depuis 1994, Tamar Jablonski-Perec apporte des décennies d'expertise en leadership dans le domaine de la chimiothérapie de la leucémie au Hadassah Medical Center.

• Professeur d'oncologie à l'Université hébraïque depuis 2006
• A effectué un fellowship en oncologie au Sloan-Kettering Cancer Center
• A reçu la bourse d'excellence de l'École de médecine Hadassah
• Membre de multiples communautés internationales de recherche sur le cancer

Le Dr Spielberg est spécialisé en chimiothérapie de la leucémie au Centre médical Assuta.

• Onco-hématologue axé sur les cancers du sang
• Exerce dans l'un des principaux centres médicaux d'Israël
• Fournit des plans de traitement personnalisés pour les patients atteints de leucémie

Dr. Mahmoud M. El Zembely is a pediatric oncologist and malignant hematologist. He manages acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. He treats Hodgkin and non‑Hodgkin lymphomas, nephroblastoma, neuroblastoma, and bone and liver tumors. His work includes gonadal and extragonadal germ cell tumors, rhabdomyosarcoma, and non‑rhabdomyosarcoma soft tissue sarcomas. He also cares for rare cancers and survivorship.

Accreditations: M.B.B.Ch, Assiut University, 2006. Master’s in Pediatric Oncology and Malignant Hematology, 2011. Clinical fellowship in pediatric bone marrow transplantation, Seattle Cancer Care Alliance, 2015–2017. Doctorate, 2020.

Roles: South Egypt Cancer Institute–Assiut University: Pediatric Oncology, 2008–2012. Assistant Lecturer, 2012–2019. Lecturer, 2020–2024. Shefa Al‑Orman Cancer Center, Luxor: Head of Pediatric Oncology, 2020–present.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Spécialisé(e) en oncologie et radiologie au Centre Médical Assuta.

• Expérimenté dans les protocoles de chimiothérapie pour la leucémie
• Combine l'expertise en oncologie et en radiologie
• Exerce dans un centre médical de premier plan

Médecin-chef du Centre d'oncologie de l'Assuta Medical Center – un chef de file dans les soins du cancer, avec un accent sur le traitement de la leucémie.

• Oncologue spécialisé(e) dans les protocoles de chimiothérapie
• Prend en charge les cas complexes de leucémie dans un centre médical de premier plan
• Dirige les programmes de traitement du Centre d'oncologie